E-type prostanoid receptor 4 (EP4) in disease and therapy

Pharmacology and Therapeutics

Volumn 138, Issue 3, 2013, Pages 485-502

  Konya, Viktoria ^a   Marsche, Gunther ^a   Schuligoi, Rufina ^a   Heinemann, Akos ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Cancerogenesis; Inflammation; Osteoporosis; Prostaglandins; Renal function; Vascular disease

Indexed keywords

7 [5 (4 BIPHENYLYLMETHOXY) 2 MORPHOLINO 3 OXOCYCLOPENTYL] 4 HEPTENOIC ACID; AGN 205203; APS 999 NA; BGC 20 1531; CAY 10598; CJ 023 423; CJ 042 794; CP 044 519 02; DIPHENYLOXAZOLE 8; EP 4 RAG; ER 819762; GAMMA LACTAM DERIVATIVE; GW 627368 X; L 161982; L 902688; LUBIPROSTONE; MF 191; MF 498; ONO AE 1 329; ONO AE 1 734; ONO AE 2 227; ONO AE 3 208; PGE 1 OH; PROSTAGLANDIN E RECEPTOR 4; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; PROSTAGLANDIN RECEPTOR STIMULATING AGENT; RIVENPROST; TCS 2510; UNCLASSIFIED DRUG;

ANGIOGENESIS; ATHEROSCLEROSIS; CD4+ T LYMPHOCYTE; CELL PROLIFERATION; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENDRITIC CELL; DUCTUS ARTERIOSUS; EOSINOPHIL; GASTROINTESTINAL TRACT; HUMAN; IMMUNOMODULATION; MACROPHAGE; METASTASIS; NEOPLASM; NONHUMAN; OSTEOCLASTOGENESIS; OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; REVIEW; SEPSIS; SIGNAL TRANSDUCTION; TH17 CELL; THROMBOCYTE AGGREGATION; VASCULARIZATION;

ANIMALS; BONE DISEASES; CARDIOVASCULAR DISEASES; DINOPROSTONE; GASTROINTESTINAL DISEASES; HUMANS; IMMUNOLOGIC FACTORS; KIDNEY DISEASES; LUNG DISEASES; NEOPLASMS; RECEPTORS, PROSTAGLANDIN E, EP4 SUBTYPE;

EID: 84877575771     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2013.03.006     Document Type: Review

References (280)

1. S. Aggarwal, Y.P. Moodley, P.J. Thompson, and N.L. Misso Prostaglandin E-2 and cysteinyl leukotriene concentrations in sputum: association with asthma severity and eosinophilic inflammation Clin Exp Allergy 40 2010 85 93
2. S.A. Aguirre, W. Huang, G. Prasanna, and B. Jessen Corneal neovascularization and ocular irritancy responses in dogs following topical ocular administration of an EP4-prostaglandin E2 agonist Toxicol Pathol 37 2009 911 920
3. E. Aihara, Y. Nomura, Y. Sasaki, F. Ise, K. Kita, and K. Takeuchi Involvement of prostaglandin E receptor EP3 subtype in duodenal bicarbonate secretion in rats Life Sci 80 2007 2446 2453
4. A. Alfranca, M.A. Iniguez, M. Fresno, and J.M. Redondo Prostanoid signal transduction and gene expression in the endothelium: role in cardiovascular diseases Cardiovasc Res 70 2006 446 456
5. L. Aoudjit, A. Potapov, and T. Takano Prostaglandin E2 promotes cell survival of glomerular epithelial cells via the EP4 receptor Am J Physiol Renal Fluid Electrolyte Physiol 290 2006 F1534 F1542
6. H. Araki, H. Ukawa, Y. Sugawa, K. Yagi, K. Suzuki, and K. Takeuchi The roles of prostaglandin E receptor subtypes in the cytoprotective action of prostaglandin E2 in rat stomach Aliment Pharmacol Ther 14 Suppl. 1 2000 116 124
7. S. Arns, R. Gibe, A. Moreau, M.M. Morshed, and R.N. Young Design and synthesis of novel bone-targeting dual-action pro-drugs for the treatment and reversal of osteoporosis Bioorg Med Chem 20 2012 2131 2140
8. H. Aso, S. Ito, A. Mori, M. Morioka, N. Suganuma, and M. Kondo Prostaglandin E2 enhances interleukin-8 production via EP4 receptor in human pulmonary microvascular endothelial cells Am J Physiol Lung Cell Mol Physiol 302 2012 L266 L273
9. H. Aso, S. Ito, A. Mori, N. Suganuma, M. Morioka, and N. Takahara Differential regulation of airway smooth muscle cell migration by e-prostanoid receptor subtypes Am J Respir Cell Mol Biol 48 2013 322 329
10. M. Attur, H.E. Al-Mussawir, J. Patel, A. Kitay, M. Dave, and G. Palmer Prostaglandin E2 exerts catabolic effects in osteoarthritis cartilage: evidence for signaling via the EP4 receptor J Immunol 181 2008 5082 5088
11. V.R. Babaev, J.D. Chew, L. Ding, S. Davis, M.D. Breyer, and R.M. Breyer Macrophage EP4 deficiency increases apoptosis and suppresses early atherosclerosis Cell Metab 8 2008 492 501
12. S.K. Banu, J. Lee, V.O. Speights Jr.; A. Starzinski-Powitz, and J.A. Arosh Selective inhibition of prostaglandin E2 receptors EP2 and EP4 induces apoptosis of human endometriotic cells through suppression of ERK1/2, AKT, NFkappaB, and beta-catenin pathways and activation of intrinsic apoptotic mechanisms Mol Endocrinol 23 2009 1291 1305
13. F. Baratelli, K. Krysan, N. Heuze-Vourc'h, L. Zhu, B. Escuadro, and S. Sharma PGE2 confers survivin-dependent apoptosis resistance in human monocyte-derived dendritic cells J Leukoc Biol 78 2005 555 564
14. A.K. Bassil, R.A. Borman, E.M. Jarvie, R.J. McArthur-Wilson, R. Thangiah, and E.Z. Sung Activation of prostaglandin EP receptors by lubiprostone in rat and human stomach and colon Br J Pharmacol 154 2008 126 135
15. M. Bastepe, and B. Ashby Identification of a region of the C-terminal domain involved in short-term desensitization of the prostaglandin EP4 receptor Br J Pharmacol 126 1999 365 371
16. C. Benyahia, I. Gomez, L. Kanyinda, K. Boukais, C. Danel, and G. Leseche PGE(2) receptor (EP4) agonists: potent dilators of human bronchi and future asthma therapy? Pulm Pharmacol Ther 25 2012 115 118
17. X. Billot, A. Chateauneuf, N. Chauret, D. Denis, G. Greig, and M.C. Mathieu Discovery of a potent and selective agonist of the prostaglandin EP4 receptor Bioorg Med Chem Lett 13 2003 1129 1132
18. A.A. Birukova, T. Zagranichnaya, P. Fu, E. Alekseeva, W. Chen, and J.R. Jacobson Prostaglandins PGE(2) and PGI(2) promote endothelial barrier enhancement via PKA- and Epac1/Rap1-dependent Rac activation Exp Cell Res 313 2007 2504 2520
19. I. Bjarnason, J. Hayllar, A.J. Macpherson, and A.S. Russell Side-effects of nonsteroidal antiinflammatory drugs on the small and large-intestine in humans Gastroenterology 104 1993 1832 1847
20. K. Boniface, K.S. Bak-Jensen, Y. Li, W.M. Blumenschein, M.J. McGeachy, and T.K. McClanahan Prostaglandin E2 regulates Th17 cell differentiation and function through cyclic AMP and EP2/EP4 receptor signaling J Exp Med 206 2009 535 548
21. J.L. Bos Epac: a new cAMP target and new avenues in cAMP research Nat Rev Mol Cell Biol 4 2003 733 738
22. R.M. Breyer, L.S. Davis, C.L. Nian, R. Redha, B. Stillman, and H.R. Jacobson Cloning and expression of the rabbit prostaglandin EP(4) receptor Am J Physiol Renal Fluid Electrolyte Physiol 270 1996 F485 F493
23. M. Bruegel, U. Ludwig, A. Kleinhempel, S. Petros, L. Kortz, and U. Ceglarek Sepsis-associated changes of the arachidonic acid metabolism and their diagnostic potential in septic patients Crit Care Med 40 2012 1478 1486
24. F.G. Buchanan, D.L. Gorden, P. Matta, Q. Shi, L.M. Matrisian, and R.N. DuBois Role of beta-arrestin 1 in the metastatic progression of colorectal cancer Proc Natl Acad Sci U S A 103 2006 1492 1497
25. J. Buckley, M.A. Birrell, S.A. Maher, A.T. Nials, D.L. Clarke, and M.G. Belvisi EP4 receptor as a new target for bronchodilator therapy Thorax 66 2011 1029 1035
26. K.T. Bunce, and C.F. Spraggs Prostanoid stimulation of anion secretion in guinea-pig gastric and ileal mucosa is mediated by different receptors Br J Pharmacol 101 1990 889 895
27. R.Y. Cao, T. St Amand, X. Li, S.H. Yoon, C.P. Wang, and H. Song Prostaglandin receptor EP4 in abdominal aortic aneurysms Am J Pathol 181 2012 313 321
28. R.D. Catalano, M.R. Wilson, S.C. Boddy, A.T. McKinlay, K.J. Sales, and H.N. Jabbour Hypoxia and prostaglandin E receptor 4 signalling pathways synergise to promote endometrial adenocarcinoma cell proliferation and tumour growth PLoS One 6 2011 e19209
29. I. Cebola, and M.A. Peinado Epigenetic deregulation of the COX pathway in cancer Prog Lipid Res 51 2012 301 313
30. S.D. Chell, I.R. Witherden, R.R. Dobson, M. Moorghen, A.A. Herman, and D. Qualtrough Increased EP4 receptor expression in colorectal cancer progression promotes cell growth and anchorage independence Cancer Res 66 2006 3106 3113
31. Q. Chen, K. Muramoto, N. Masaaki, Y. Ding, H. Yang, and M. Mackey A novel antagonist of the prostaglandin E(2) EP(4) receptor inhibits Th1 differentiation and Th17 expansion and is orally active in arthritis models Br J Pharmacol 160 2010 292 310
32. Y.C. Chuang, P. Tyagi, C.C. Huang, M.B. Chancellor, and N. Yoshimura Mechanisms and urodynamic effects of a potent and selective EP4 receptor antagonist, MF191, on cyclophosphamide and prostaglandin E(2)-induced bladder overactivity in rats Br J Urol Int 110 2012 1558 1564
33. P. Clark, S.E. Rowland, D. Denis, M.C. Mathieu, R. Stocco, and H. Poirier MF498 [N-{[4-(5,9-diethoxy-6-oxo-6,8-dihydro-7H-pyrrolo[3,4-g]quinolin-7-yl)-3- methylbe nzyl]sulfonyl}-2-(2-methoxyphenyl)acetamide], a selective E prostanoid receptor 4 antagonist, relieves joint inflammation and pain in rodent models of rheumatoid and osteoarthritis J Pharmacol Exp Ther 325 2008 425 434
34. R.A. Coleman, S.P. Grix, S.A. Head, J.B. Louttit, A. Mallett, and R.L.G. Sheldrick A novel inhibitory prostanoid receptor in piglet saphenous-vein Prostaglandins 47 1994 151 168
35. J. Colucci, M. Boyd, C. Berthelette, J.F. Chiasson, Z. Wang, and Y. Ducharme Discovery of 4-[1-[([1-[4-(trifluoromethyl)benzyl]-1H-indol-7-yl] carbonyl)amino]cyclopropyl]be nzoic acid (MF-766), a highly potent and selective EP4 antagonist for treating inflammatory pain Bioorg Med Chem Lett 20 2010 3760 3763
36. T. Coskun, L.S. O'Farrell, S.K. Syed, D.A. Briere, L.S. Beavers, and S.L. Dubois Activation of prostaglandin E receptor 4 triggers secretion of gut hormone peptides GLP-1, GLP-2, and PYY Endocrinology 154 2013 45 53
37. S.C. Cote, S. Pasvanis, S. Bounou, and N. Dumais CCR7-specific migration to CCL19 and CCL21 is induced by PGE(2) stimulation in human monocytes: involvement of EP(2)/EP(4) receptors activation Mol Immunol 46 2009 2682 2693
38. A.W. Cuthbert Lubiprostone targets prostanoid EP(4) receptors in ovine airways Br J Pharmacol 162 2011 508 520
39. M. Dagouassat, J.M. Gagliolo, S. Chrusciel, M.C. Bourin, C. Duprez, and P. Caramelle The COX2/PGE2 pathway maintains senescence of chronic obstructive pulmonary disease fibroblasts Am J Respir Crit Care Med 2013 10.1164/rccm.201208-1361OC
40. M.T. DeMeo, E.A. Mutlu, A. Keshavarzian, and M.C. Tobin Intestinal permeation and gastrointestinal disease J Clin Gastroenterol 34 2002 385 396
41. S. Desai, H. April, C. Nwaneshiudu, and B. Ashby Comparison of agonist-induced internalization of the human EP2 and EP4 prostaglandin receptors: role of the carboxyl terminus in EP4 receptor sequestration Mol Pharmacol 58 2000 1279 1286
42. S. Desai, and B. Ashby Agonist-induced internalization and mitogen-activated protein kinase activation of the human prostaglandin EP4 receptor FEBS Lett 501 2001 156 160
43. I. Dey, M.A. Giembycz, and K. Chadee Prostaglandin E(2) couples through EP(4) prostanoid receptors to induce IL-8 production in human colonic epithelial cell lines Br J Pharmacol 156 2009 475 485
44. D.M. Duffy, L.K. McGinnis, C.A. Vandevoort, and L.K. Christenson Mammalian oocytes are targets for prostaglandin E2 (PGE2) action Reprod Biol Endocrinol 8 2010 131
45. N. El-Nefiawy, K. Abdel-Hakim, and N. Kanayama The selective prostaglandin EP4 agonist, APS-999 Na, induces follicular growth and maturation in the rat ovary Eur J Endocrinol 152 2005 315 323
46. J.E. Fabre, M. Nguyen, K. Athirakul, K. Coggins, J.D. McNeish, and S. Austin Activation of the murine EP3 receptor for PGE2 inhibits cAMP production and promotes platelet aggregation J Clin Invest 107 2001 603 610
47. D. Fabricius, M. Neubauer, B. Mandel, C. Schutz, A. Viardot, and A. Vollmer Prostaglandin E2 inhibits IFN-alpha secretion and Th1 costimulation by human plasmacytoid dendritic cells via E-prostanoid 2 and E-prostanoid 4 receptor engagement J Immunol 184 2010 677 684
48. C.S. Facemire, M. Nguyen, L. Jania, W.H. Beierwaltes, H.S. Kim, and B.H. Koller A major role for the EP4 receptor in regulation of renin Am J Physiol Renal Fluid Electrolyte Physiol 301 2011 F1035 F1041
49. W.H. Faour, K. Gomi, and C.R. Kennedy PGE(2) induces COX-2 expression in podocytes via the EP(4) receptor through a PKA-independent mechanism Cell Signal 20 2008 2156 2164
50. E.R. Fedyk, and R.P. Phipps Prostaglandin E2 receptors of the EP2 and EP4 subtypes regulate activation and differentiation of mouse B lymphocytes to IgE-secreting cells Proc Natl Acad Sci U S A 93 1996 10978 10983
51. J.B. Felder, B.I. Korelitz, R. Rajapakse, S. Schwarz, A.P. Horatagis, and G. Gleim Effects of nonsteroidal antiinflammatory drugs on inflammatory bowel disease: a case-control study Am J Gastroenterol 95 2000 1949 1954
52. E.F. Fleming, K. Athirakul, M.I. Oliverio, M. Key, J. Goulet, and B.H. Koller Urinary concentrating function in mice lacking EP3 receptors for prostaglandin E2 Am J Physiol 275 1998 F955 F961
53. S.M. Foord, B. Marks, M. Stolz, E. Bufflier, N.J. Fraser, and M.G. Lee The structure of the prostaglandin EP4 receptor gene and related pseudogenes Genomics 35 1996 182 188
54. N. Foudi, L. Kotelevets, L. Louedec, G. Leseche, D. Henin, and E. Chastre Vasorelaxation induced by prostaglandin E(2) in human pulmonary vein: role of the EP(4) receptor subtype Br J Pharmacol 154 2008 1631 1639
55. U.G. Friis, J. Stubbe, T.R. Uhrenholt, P. Svenningsen, R.M. Nusing, and O. Skott Prostaglandin E2 EP2 and EP4 receptor activation mediates cAMP-dependent hyperpolarization and exocytosis of renin in juxtaglomerular cells Am J Physiol Renal Fluid Electrolyte Physiol 289 2005 F989 F997
56. S. Frolich, A. Olliges, N. Kern, Y. Schreiber, S. Narumiya, and R.M. Nusing Temporal expression of the PGE2 synthetic system in the kidney is associated with the time frame of renal developmental vulnerability to cyclooxygenase-2 inhibition Am J Physiol Renal Fluid Electrolyte Physiol 303 2012 F209 F219
57. H. Fujino, and J.W. Regan EP4 prostanoid receptor coupling to a pertussis toxin-sensitive inhibitory G protein Mol Pharmacol 69 2006 13 18
58. H. Fujino, K.A. West, and J.W. Regan Phosphorylation of glycogen synthase kinase-3 and stimulation of T-cell factor signaling following activation of EP2 and EP4 prostanoid receptors by prostaglandin E-2 J Biol Chem 277 2002 2614 2619
59. H. Fujino, W. Xu, and J.W. Regan Prostaglandin E-2 induced functional expression of early growth response factor-1 by EP4, but not EP2, prostanoid receptors via the phosphatidylinositol 3-kinase and extracellular signal-regulated kinases J Biol Chem 278 2003 12151 12156
60. Y. Fukuda, M. Sugimura, K. Suzuki, and N. Kanayama Prostaglandin E2 receptor EP4-selective antagonist inhibits lipopolysaccharide-induced cervical ripening in rabbits Acta Obstet Gynecol Scand 86 2007 1297 1302
61. H. Funahashi, M. Satake, S. Hasan, H. Sawai, R.A. Newman, and H.A. Reber Opposing effects of n - 6 and n - 3 polyunsaturated fatty acids on pancreatic cancer growth Pancreas 36 2008 353 362
62. C.D. Funk, and G.A. FitzGerald COX-2 inhibitors and cardiovascular risk J Cardiovasc Pharmacol 50 2007 470 479
63. K. Fushimi, S. Nakashima, F. You, M. Takigawa, and K. Shimizu Prostaglandin E2 downregulates TNF-alpha-induced production of matrix metalloproteinase-1 in HCS-2/8 chondrocytes by inhibiting Raf-1/MEK/ERK cascade through EP4 prostanoid receptor activation J Cell Biochem 100 2007 783 793
64. G.L. Galea, A. Sunters, L.B. Meakin, G. Zaman, T. Sugiyama, and L.E. Lanyon Sost down-regulation by mechanical strain in human osteoblastic cells involves PGE2 signaling via EP4 FEBS Lett 585 2011 2450 2454
65. S.H. Gavett, S.L. Madison, P.C. Chulada, P.E. Scarborough, W. Qu, and J.E. Boyle Allergic lung responses are increased in prostaglandin H synthase-deficient mice J Clin Invest 104 1999 721 732
66. R. Gentile, G. Stevenson, T. Dooley, D. Franklin, I. Kawabori, and A. Pearlman Pulsed Doppler echocardiographic determination of time of ductal closure in normal newborn infants Journal of Pediatrics 98 1981 443 448
67. S. Gross, P. Tilly, D. Hentsch, J.-L. Vonesch, and J.-E. Fabre Vascular wall-produced prostaglandin E2 exacerbates arterial thrombosis and atherothrombosis through platelet EP3 receptors J Exp Med 204 2007 311 320
68. T. Grosser, S. Fries, and G.A. FitzGerald Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities J Clin Invest 116 2006 4 15
69. T. Grosser, Y. Yu, and G.A. FitzGerald Emotion recollected in tranquility: lessons learned from the COX-2 saga Annu Rev Med 61 2010 17 33
70. + absorption by activating the EP1 receptor J Clin Invest 102 1998 194 201
71. K. Hamaguchi, N. Yamamoto, T. Nakagawa, T. Furuyashiki, S. Narumiya, and J. Ito Role of PGE-type receptor 4 in auditory function and noise-induced hearing loss in mice Neuropharmacology 62 2012 1841 1847
72. C.M. Hao, and M.D. Breyer Physiological regulation of prostaglandins in the kidney Annu Rev Physiol 70 2008 357 377
73. S. Harirforoosh, and F. Jamali Renal adverse effects of nonsteroidal anti-inflammatory drugs Expert Opin Drug Saf 8 2009 669 681
74. R.E. Harris Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung Inflammopharmacology 17 2009 55 67
75. R. Hatazawa, A. Tanaka, M. Tanigami, K. Amagase, S. Kato, and Y. Ashida Cyclooxygenase-2/prostaglandin E2 accelerates the healing of gastric ulcers via EP4 receptors Am J Physiol Gastrointest Liver Physiol 293 2007 G788 G797
76. Y. Hattori, T. Ohno, T. Ae, T. Saeki, K. Arai, and S. Mizuguchi Gastric mucosal protection against ethanol by EP2 and EP4 signaling through the inhibition of leukotriene C4 production Am J Physiol Gastrointest Liver Physiol 294 2008 G80 G87
77. K. Hattori, A. Tanaka, N. Fujii, H. Takasugi, Y. Tenda, and M. Tomita Discovery of diphenyloxazole and Ndelta-Z-ornithine derivatives as highly potent and selective human prostaglandin EP(4) receptor antagonists J Med Chem 48 2005 3103 3106
78. G. Hawcroft, C.W. Ko, and M.A. Hull Prostaglandin E2-EP4 receptor signalling promotes tumorigenic behaviour of HT-29 human colorectal cancer cells Oncogene 26 2007 3006 3019
79. Z. Hazan-Eitan, Y. Weinstein, N. Hadad, A. Konforty, and R. Levy Induction of Fc gammaRIIA expression in myeloid PLB cells during differentiation depends on cytosolic phospholipase A2 activity and is regulated via activation of CREB by PGE2 Blood 108 2006 1758 1766
80. S. Heptinstall, D.I. Espinosa, P. Manolopoulos, J.R. Glenn, A.E. White, and A. Johnson DG-041 inhibits the EP3 prostanoid receptorA new target for inhibition of platelet function in atherothrombotic disease Platelets 19 2008 605 613
81. S.J. Hewett, S.C. Bell, and J.A. Hewett Contributions of cyclooxygenase-2 to neuroplasticity and neuropathology of the central nervous system Pharmacol Ther 112 2006 335 357
82. K. Hishikari, J.-i Suzuki, M. Ogawa, K. Isobe, T. Takahashi, and M. Onishi Pharmacological activation of the prostaglandin E-2 receptor EP4 improves cardiac function after myocardial ischaemia/reperfusion injury Cardiovasc Res 81 2009 123 132
83. D. Holt, X. Ma, N. Kundu, and A. Fulton Prostaglandin E(2) (PGE (2)) suppresses natural killer cell function primarily through the PGE(2) receptor EP4 Cancer Immunol Immunother 60 2011 1577 1586
84. A. Honda, Y. Sugimoto, T. Namba, A. Watabe, A. Irie, and M. Negishi Cloning and expression of a cDNA for mouse prostaglandin E receptor EP2 subtype J Biol Chem 268 1993 7759 7762
85. R. Hori, T. Nakagawa, N. Yamamoto, K. Hamaguchi, and J. Ito Role of prostaglandin E receptor subtypes EP2 and EP4 in autocrine and paracrine functions of vascular endothelial growth factor in the inner ear BMC Neurosci 11 2010 35
86. T. Hoshino, T. Namba, M. Takehara, N. Murao, T. Matsushima, and Y. Sugimoto Improvement of cognitive function in Alzheimer's disease model mice by genetic and pharmacological inhibition of the EP(4) receptor J Neurochem 120 2012 795 805
87. T. Hoshino, S. Tsutsumi, W. Tomisato, H.J. Hwang, T. Tsuchiya, and T. Mizushima Prostaglandin E2 protects gastric mucosal cells from apoptosis via EP2 and EP4 receptor activation J Biol Chem 278 2003 12752 12758
88. K. Hosono, T. Suzuki, H. Tamaki, H. Sakagami, I. Hayashi, and S. Narumiya Roles of prostaglandin E2-EP3/EP4 receptor signaling in the enhancement of lymphangiogenesis during fibroblast growth factor-2-induced granulation formation Arterioscler Thromb Vasc Biol 31 2011 1049 1058
89. R.S. Hotchkiss, and I.E. Karl Medical progress: the pathophysiology and treatment of sepsis N Engl J Med 348 2003 138 150
90. A.-M. Hristovska, L.E. Rasmussen, P.B.L. Hansen, S.S. Nielsen, R.M. Nuesing, and S. Narumiya Prostaglandin E-2 induces vascular relaxation by E-prostanoid 4 receptor-mediated activation of endothelial nitric oxide synthase Hypertension 50 2007 525 530
91. S.K. Huang, E.S. White, S.H. Wettlaufer, H. Grifka, C.M. Hogaboam, and V.J. Thannickal Prostaglandin E(2) induces fibroblast apoptosis by modulating multiple survival pathways FASEB J 23 2009 4317 4326
92. T. Inazumi, N. Shirata, K. Morimoto, H. Takano, E. Segi-Nishida, and Y. Sugimoto Prostaglandin E(2)-EP4 signaling suppresses adipocyte differentiation in mouse embryonic fibroblasts via an autocrine mechanism J Lipid Res 52 2011 1500 1508
93. K.N. Ivey, and D. Srivastava The paradoxical patent ductus anteriosus J Clin Invest 116 2006 2863 2866
94. K. Iwasaki, K. Noguchi, H. Endo, H. Kondo, and I. Ishikawa Prostaglandin E-2 downregulates interleukin-12 production through EP4 receptors in human monocytes stimulated with lipopolysaccharide from Actinobacillus actinomycetemcomitans and interferon-gamma Oral Microbiol Immunol 18 2003 150 155
95. D. Iyu, J.R. Glenn, A.E. White, A.J. Johnson, S.C. Fox, and S. Heptinstall The role of prostanoid receptors in mediating the effects of PGE(2) on human platelet function Platelets 21 2010 329 342
96. R.L. Jakab, A.M. Collaco, and N.A. Ameen Lubiprostone targets prostanoid signaling and promotes ion transporter trafficking, mucus exocytosis, and contractility Dig Dis Sci 57 2012 2826 2845
97. B.L. Jensen, B. Mann, O. Skott, and A. Kurtz Differential regulation of renal prostaglandin receptor mRNAs by dietary salt intake in the rat Kidney Int 56 1999 528 537
98. G.-L. Jiang, A. Nieves, W.B. Im, D.W. Old, D.T. Dinh, and L. Wheeler The prevention of colitis by E prostanoid receptor 4 agonist through enhancement of epithelium survival and regeneration J Pharmacol Exp Ther 320 2007 22 28
99. P. Jimenez, E. Piazuelo, C. Cebrian, J. Ortego, M. Strunk, and M.A. Garcia-Gonzalez Prostaglandin EP2 receptor expression is increased in Barrett's oesophagus and oesophageal adenocarcinoma Aliment Pharmacol Ther 31 2010 440 451
100. H. Jing, E. Vassiliou, and D. Ganea Prostaglandin E2 inhibits production of the inflammatory chemokines CCL3 and CCL4 in dendritic cells J Leukoc Biol 74 2003 868 879
101. M. Johannessen, M.P. Delghandi, and U. Moens What turns CREB on? Cell Signal 16 2004 1211 1227
102. M. Johannessen, and U. Moens Multisite phosphorylation of the cAMP response element-binding protein (CREB) by a diversity of protein kinases Front Biosci 12 2007 1814 1832
103. N.S. Joo, J.J. Wine, and A.W. Cuthbert Lubiprostone stimulates secretion from tracheal submucosal glands of sheep, pigs, and humans Am J Physiol Lung Cell Mol Physiol 296 2009 L811 L824
104. A.P. Joy, and E.A. Cowley 8-Iso-PGE2 stimulates anion efflux from airway epithelial cells via the EP4 prostanoid receptor Am J Respir Cell Mol Biol 38 2008 143 152
105. K. Kabashima, T. Saji, T. Murata, M. Nagamachi, T. Matsuoka, and E. Segi The prostaglandin receptor EP4 suppresses colitis, mucosal damage and CD4 cell activation in the gut J Clin Invest 109 2002 883 893
106. K. Kabashima, D. Sakata, M. Nagamachi, Y. Miyachi, K. Inaba, and S. Narumiya Prostaglandin E2-EP4 signaling initiates skin immune responses by promoting migration and maturation of Langerhans cells Nat Med 9 2003 744 749
107. P. Kalinski Regulation of immune responses by prostaglandin E2 J Immunol 188 2012 21 28
108. T. Kambe, T. Maruyama, Y. Nakai, H. Oida, N. Abe, and A. Nishiura Synthesis and evaluation of gamma-lactam analogs of PGE(2) as EP4 and EP2/EP4 agonists Bioorg Med Chem 20 2012 3502 3522
109. A. Kambe, H. Yoshioka, H. Kamitani, T. Watanabe, S.J. Baek, and T.E. Eling The cyclooxygenase inhibitor sulindac sulfide inhibits EP4 expression and suppresses the growth of glioblastoma cells Cancer Prev Res (Phila) 2 2009 1088 1099
110. H.J. Kaufmann, and H.L. Taubin Nonsteroidal anti-inflammatory drugs activate quiescent inflammatory bowel disease Ann Intern Med 107 1987 513 516
111. V. Konya, S. Philipose, Z. Balint, A. Olschewski, G. Marsche, and E.M. Sturm Interaction of eosinophils with endothelial cells is modulated by prostaglandin EP4 receptors Eur J Immunol 41 2011 2379 2389
112. V. Konya, A. Ullen, N. Kampitsch, A. Theiler, S. Philipose, and G.P. Parzmair Endothelial E-type prostanoid 4 receptors promote barrier function and inhibit neutrophil trafficking J Allergy Clin Immunol 131 2013 532-540 e531-532
113. K.L. Kopp, C.S. Kauczok, B. Lauenborg, T. Krejsgaard, K.W. Eriksen, and Q. Zhang COX-2-dependent PGE(2) acts as a growth factor in mycosis fungoides (MF) Leukemia 24 2010 1179 1185
114. S. Kubo, H.K. Takahashi, M. Takei, H. Iwagaki, T. Yoshino, and N. Tanaka E-prostanoid (EP)2/EP4 receptor-dependent maturation of human monocyte-derived dendritic cells and induction of helper T2 polarization J Pharmacol Exp Ther 309 2004 1213 1220
115. I. Kudo, and M. Murakami Prostaglandin E synthase, a terminal enzyme for prostaglandin E2 biosynthesis J Biochem Mol Biol 38 2005 633 638
116. N. Kundu, X. Ma, D. Holt, O. Goloubeva, S. Ostrand-Rosenberg, and A.M. Fulton Antagonism of the prostaglandin E receptor EP4 inhibits metastasis and enhances NK function Breast Cancer Res Treat 117 2009 235 242
117. T. Kunikata, H. Araki, M. Takeeda, S. Kato, and K. Takeuchi Prostaglandin E prevents indomethacin-induced gastric and intestinal damage through different EP receptor subtypes J Physiol Paris 95 2001 157 163
118. T. Kunikata, A. Tanaka, T. Miyazawa, S. Kato, and K. Takeuchi 16,16-Dimethyl prostaglandin E2 inhibits indomethacin-induced small intestinal lesions through EP3 and EP4 receptors Dig Dis Sci 47 2002 894 904
119. T. Kunikata, H. Yamane, E. Segi, T. Matsuoka, Y. Sugimoto, and S. Tanaka Suppression of allergic inflammation by the prostaglandin E receptor subtype EP3 Nat Immunol 6 2005 524 531
120. Y. Kurihara, H. Endo, T. Akahoshi, and H. Kondo Up-regulation of prostaglandin E receptor EP2 and EP4 subtypes in rat synovial tissues with adjuvant arthritis Clin Exp Immunol 123 2001 323 330
121. S. Kuriyama, H. Kashiwagi, K.-i Yuhki, F. Kojima, T. Yamada, and T. Fujino Selective activation of the prostaglandin E-2 receptor subtype EP2 or EP4 leads to inhibition of platelet aggregation Thromb Haemost 104 2010 796 803
122. Y. Kuzumoto, M. Sho, N. Ikeda, K. Hamada, T. Mizuno, and S. Akashi Significance and therapeutic potential of prostaglandin E-2 receptor in hepatic ischemia/reperfusion injury in mice Hepatology 42 2005 608 617
123. L. Laine, K. Takeuchi, and A. Tarnawski Gastric mucosal defense and cytoprotection: bench to bedside Gastroenterology 135 2008 41 60
124. M. Leduc, B. Breton, C. Gales, C. Le Gouill, M. Bouvier, and S. Chemtob Functional selectivity of natural and synthetic prostaglandin EP(4) receptor ligands J Pharmacol Exp Ther 331 2009 297 307
125. J. Lee, S.K. Banu, T. Subbarao, A. Starzinski-Powitz, and J.A. Arosh Selective inhibition of prostaglandin E2 receptors EP2 and EP4 inhibits invasion of human immortalized endometriotic epithelial and stromal cells through suppression of metalloproteinases Mol Cell Endocrinol 332 2011 306 313
126. J.H. Li, C.L. Chou, B. Li, O. Gavrilova, C. Eisner, and J. Schnermann A selective EP4 PGE2 receptor agonist alleviates disease in a new mouse model of X-linked nephrogenic diabetes insipidus J Clin Invest 119 2009 3115 3126
127. T. Li, J. Qi, and E.A. Cowley Activation of the EP(4) prostanoid receptor induces prostaglandin E(2) and pro-inflammatory cytokine production in human airway epithelial cells Pulm Pharmacol Ther 24 2011 42 48
128. Y.J. Li, X.Q. Wang, T. Sato, N. Kanaji, M. Nakanishi, and M. Kim Prostaglandin E-2 inhibits human lung fibroblast chemotaxis through disparate actions on different E-prostanoid receptors Am J Respir Cell Mol Biol 44 2011 99 107
129. X. Liang, L. Lin, N.S. Woodling, Q. Wang, C. Anacker, and T. Pan Signaling via the prostaglandin E-2 receptor EP4 exerts neuronal and vascular protection in a mouse model of cerebral ischemia J Clin Invest 121 2011 4362 4371
130. Y. Liu, M. Rajagopal, K. Lee, L. Battini, D. Flores, and G.L. Gusella Prostaglandin E2 mediates proliferation and chloride secretion in ADPKD cystic renal epithelia Am J Physiol Renal Fluid Electrolyte Physiol 303 2012 F1425 F1434
131. A. Ludwig, J.E. Ehlert, H.D. Flad, and E. Brandt Identification of distinct surface-expressed and intracellular CXC-chemokine receptor 2 glycoforms in neutrophils: N-glycosylation is essential for maintenance of receptor surface expression J Immunol 165 2000 1044 1052
132. T. Luft, M. Jefford, P. Luetjens, T. Toy, H. Hochrein, and K.A. Masterman Functionally distinct dendritic cell (DC) populations induced by physiologic stimuli: prostaglandin E(2) regulates the migratory capacity of specific DC subsets Blood 100 2002 1362 1372
133. P. Luschnig-Schratl, E.M. Sturm, V. Konya, S. Philipose, G. Marsche, and E. Froehlich EP4 receptor stimulation down-regulates human eosinophil function Cell Mol Life Sci 68 2011 3573 3587
134. H. Ma, A. Hara, C.Y. Xiao, Y. Okada, O. Takahata, and K. Nakaya Increased bleeding tendency and decreased susceptibility to thromboembolism in mice lacking the prostaglandin E receptor subtype EP3 Circulation 104 2001 1176 1180
135. X. Ma, N. Kundu, S. Rifat, T. Walser, and A.M. Fulton Prostaglandin E receptor EP4 antagonism inhibits breast cancer metastasis Cancer Res 66 2006 2923 2927
136. S. Malek, T. Huxford, and G. Ghosh I kappa B alpha functions through direct contacts with the nuclear localization signals and the DNA binding sequences of NF-kappa B J Biol Chem 273 1998 25427 25435
137. G.F. Mao, J.G. Jin, M. Bastepe, S. OrtizVega, and B. Ashby Prostaglandin E(2) both stimulates and inhibits adenyl cyclase on platelets: comparison of effects on cloned EP4 and EP3 prostaglandin receptor subtypes Prostaglandins 52 1996 175 185
138. D. Margan, A. Borota, M. Mracec, and M. Mracec 3D homology model of the human prostaglandin E2 receptor EP4 subtype Rev Roum Chim 57 2012 39 44
139. J.G. Martin, M. Suzuki, K. Maghni, R. Pantano, D. Ramos-Barbon, and D. Ihaku The immunomodulatory actions of prostaglandin E-2 on allergic airway responses in the rat J Immunol 169 2002 3963 3969
140. L. Martinet, C. Jean, G. Dietrich, J.J. Fournie, and R. Poupot PGE2 inhibits natural killer and gamma delta T cell cytotoxicity triggered by NKR and TCR through a cAMP-mediated PKA type I-dependent signaling Biochem Pharmacol 80 2010 838 845
141. T. Maruyama, S.I. Kuwabe, Y. Kawanaka, T. Shiraishi, Y. Shinagawa, and K. Sakata Design and synthesis of a selective EP4-receptor agonist. Part 4: practical synthesis and biological evaluation of a novel highly selective EP4-receptor agonist Bioorg Med Chem 10 2002 2103 2110
142. N. Masaki, Y. Ohta, H. Shirataki, I. Ogata, S. Hayashi, and S. Yamada Hepatocyte membrane stabilization by prostaglandins E1 and E2: favorable effects on rat liver injury Gastroenterology 102 1992 572 576
143. K. Masuko, M. Murata, K. Yudoh, H. Shimizu, M. Beppu, and H. Nakamura Prostaglandin E2 regulates the expression of connective tissue growth factor (CTGF/CCN2) in human osteoarthritic chondrocytes via the EP4 receptor BMC Res Notes 3 2010 5
144. J.S. Matthews, and R.L. Jones Potentiation of aggregation and inhibition of adenylate cyclase in human platelets by prostaglandin E analogues Br J Pharmacol 108 1993 363 369
145. K.A. Maubach, R.J. Davis, D.E. Clark, G. Fenton, P.M. Lockey, and K.L. Clark BGC20-1531, a novel, potent and selective prostanoid EP receptor antagonist: a putative new treatment for migraine headache Br J Pharmacol 156 2009 316 327
146. J.M. McCoy, J.R. Wicks, and L.P. Audoly The role of prostaglandin E2 receptors in the pathogenesis of rheumatoid arthritis J Clin Invest 110 2002 651 658
147. A. McIlroy, G. Caron, S. Blanchard, I. Fremaux, D. Duluc, and Y. Delneste Histamine and prostaglandin E up-regulate the production of Th2-attracting chemokines (CCL17 and CCL22) and down-regulate IFN-gamma-induced CXCL10 production by immature human dendritic cells Immunology 117 2006 507 516
148. E. Melillo, K.L. Woolley, P.J. Manning, R.M. Watson, and P.M. O'Byrne Effect of inhaled PGE2 on exercise-induced bronchoconstriction in asthmatic subjects Am J Respir Crit Care Med 149 1994 1138 1141
149. L. Miao, S. Grebhardt, J. Shi, I. Peipe, J. Zhang, and D. Mayer Prostaglandin E2 stimulates S100A8 expression by activating protein kinase A and CCAAT/enhancer-binding-protein-beta in prostate cancer cells Int J Biochem Cell Biol 44 2012 1919 1928
150. M. Minami, K. Shimizu, Y. Okamoto, E. Folco, M.-L. Ilasaca, and M.W. Feinberg Prostaglandin E receptor type 4-associated protein interacts directly with NF-kappa B1 and attenuates macrophage activation J Biol Chem 283 2008 9692 9703
151. Y. Miyata, S. Kanda, K. Nomata, J. Eguchi, and H. Kanetake Expression of cyclooxygenase-2 and EP4 receptor in transitional cell carcinoma of the upper urinary tract J Urol 173 2005 56 60
152. M. Miyazaki, L. Makowka, R.E. Falk, J.A. Falk, M. McDonell, and D. Venturi Protection of thermochemotherapeutic-induced lethal acute hepatic necrosis in the rat by 16,16-dimethyl prostaglandin E2 J Surg Res 34 1983 415 426
153. A.J. Moeser, M.M. Haskell, D.E. Shifflett, D. Little, B.D. Schultz, and A.T. Blikslager ClC-2 chloride secretion mediates prostaglandin-induced recovery of barrier function in ischemia-injured porcine ileum Gastroenterology 127 2004 802 815
154. A.J. Moeser, P.K. Nighot, K.J. Engelke, R. Ueno, and A.T. Blikslager Recovery of mucosal barrier function in ischemic porcine ileum and colon is stimulated by a novel agonist of the ClC-2 chloride channel, lubiprostone Am J Physiol Gastrointest Liver Physiol 292 2007 G647 G656
155. J. Moreno-Rubio, G. Herrero-Beaumont, L. Tardio, M.A. Alvarez-Soria, and R. Largo Nonsteroidal antiinflammatory drugs and prostaglandin E(2) modulate the synthesis of osteoprotegerin and RANKL in the cartilage of patients with severe
156. O. Morteau, S.G. Morham, R. Sellon, L.A. Dieleman, R. Langenbach, and O. Smithies Impaired mucosal defense to acute colonic injury in mice lacking cyclooxygenase-1 or cyclooxygenase-2 J Clin Invest 105 2000 469 478
157. A. Murase, Y. Taniguchi, H. Tonai-Kachi, K. Nakao, and J. Takada In vitro pharmacological characterization of CJ-042794, a novel, potent, and selective prostaglandin EP(4) receptor antagonist Life Sci 82 2008 226 232
158. J. Murn, O. Alibert, N. Wu, S. Tendil, and X. Gidrol Prostaglandin E2 regulates B cell proliferation through a candidate tumor suppressor, Ptger4 J Exp Med 205 2008 3091 3103
159. M. Mutoh, K. Watanabe, T. Kitamura, Y. Shoji, M. Takahashi, and T. Kawamori Involvement of prostaglandin E receptor subtype EP(4) in colon carcinogenesis Cancer Res 62 2002 28 32
160. T. Nagamatsu, H. Imai, M. Yokoi, T. Nishiyama, Y. Hirasawa, and T. Nagao Protective effect of prostaglandin EP4-receptor agonist on anti-glomerular basement membrane antibody-associated nephritis J Pharmacol Sci 102 2006 182 188
161. N. Nakagawa, K. Yuhki, J. Kawabe, T. Fujino, O. Takahata, and M. Kabara The intrinsic prostaglandin E2-EP4 system of the renal tubular epithelium limits the development of tubulointerstitial fibrosis in mice Kidney Int 82 2012 158 171
162. Y. Nakano, E. Kuroda, T. Kito, S. Uematsu, S. Akira, and A. Yokota Induction of prostaglandin E2 synthesis and microsomal prostaglandin E synthase-1 expression in murine microglia by glioma-derived soluble factors. Laboratory investigation J Neurosurg 108 2008 311 319
163. H. Nakase, Y. Fujiyama, N. Oshitani, T. Oga, K. Nonomura, and T. Matsuoka Effect of EP4 agonist (ONO-4819CD) for patients with mild to moderate ulcerative colitis refractory to 5-aminosalicylates: a randomized phase II, placebo-controlled trial Inflamm Bowel Dis 16 2010 731 733
164. J. Nakata, M. Kondo, J. Tamaoki, T. Takemiya, M. Nohara, and K. Yamagata Augmentation of allergic inflammation in the airways of cyclooxygenase-2- deficient mice Respirology 10 2005 149 156
165. S. Namkoong, C.-K. Kim, Y.-L. Cho, J.-H. Kim, H. Lee, and K.-S. Ha Forskolin increases angiogenesis through the coordinated cross-talk of PKA-dependent VEGF expression and Epac-mediated PI3K/Akt/eNOS signaling Cell Signal 21 2009 906 915
166. S. Namkoong, S.J. Lee, C.K. Kim, Y.M. Kim, H.T. Chung, and H. Lee Prostaglandin E2 stimulates angiogenesis by activating the nitric oxide/cGMP pathway in human umbilical vein endothelial cells Exp Mol Med 37 2005 588 600
167. + T cells Eur J Immunol 39 2009 1301 1312
168. M. Negishi, Y. Sugimoto, and A. Ichikawa Prostanoid receptors and their biological actions Prog Lipid Res 32 1993 417 434
169. K. Nemeth, A. Leelahavanichkul, P.S.T. Yuen, B. Mayer, A. Parmelee, and K. Doi Bone marrow stromal cells attenuate sepsis via prostaglandin E-2-dependent reprogramming of host macrophages to increase their interleukin-10 production Nat Med 15 2009 42 49
170. P.B. Ngoc, J. Suzuki, M. Ogawa, K. Hishikari, K. Takayama, and Y. Hirata The anti-inflammatory mechanism of prostaglandin E2 receptor 4 activation in rat experimental autoimmune myocarditis J Cardiovasc Pharmacol 57 2011 365 372
171. N. Nishigaki, M. Negishi, A. Honda, Y. Sugimoto, T. Namba, and S. Narumiya Identification of prostaglandin E receptor 'EP2' cloned from mastocytoma cells EP4 subtype FEBS Lett 364 1995 339 341
172. N. Nishigaki, M. Negishi, and A. Ichikawa Two G(S)-coupled prostaglandin E receptor subtypes, EP2 and EP4, differ in desensitization and sensitivity to the metabolic inactivation of the agonist Mol Pharmacol 50 1996 1031 1037
173. K. Nishitani, H. Ito, T. Hiramitsu, R. Tsutsumi, S. Tanida, and T. Kitaori PGE2 inhibits MMP expression by suppressing MKK4-JNK MAP kinase-c-JUN pathway via EP4 in human articular chondrocytes J Cell Biochem 109 2010 425 433
174. M. Nitta, I. Hirata, K. Toshina, M. Murano, K. Maemura, and N. Hamamoto Expression of the EP4 prostaglandin E2 receptor subtype with rat dextran sodium sulphate colitis: colitis suppression by a selective agonist, ONO-AE1-329 Scand J Immunol 56 2002 66 75
175. X. Norel Prostanoid receptors in the human vascular wall Scientific World Journal 7 2007 1359 1374
176. R.W. Norrdin, W.S. Jee, and W.B. High The role of prostaglandins in bone in vivo Prostaglandins Leukot Essent Fatty Acids 41 1990 139 149
177. R.M. Nusing, A. Treude, C. Weissenberger, B. Jensen, M. Bek, and C. Wagner Dominant role of prostaglandin E2 EP4 receptor in furosemide-induced salt-losing tubulopathy: a model for hyperprostaglandin E syndrome/antenatal Bartter syndrome J Am Soc Nephrol 16 2005 2354 2362
178. M.K. O'Banion Cyclooxygenase-2: molecular biology, pharmacology, and neurobiology Crit Rev Neurobiol 13 1999 45 82
179. N. Obermajer, R. Muthuswamy, J. Lesnock, R.P. Edwards, and P. Kalinski Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cells Blood 118 2011 5498 5505
180. N. Obermajer, R. Muthuswamy, K. Odunsi, R.P. Edwards, and P. Kalinski PGE(2)-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment Cancer Res 71 2011 7463 7470
181. M. Ogawa, J. Suzuki, H. Kosuge, K. Takayama, R. Nagai, and M. Isobe The mechanism of anti-inflammatory effects of prostaglandin E2 receptor 4 activation in murine cardiac transplantation Transplantation 87 2009 1645 1653
182. O. Ogunwobi, G. Mutungi, and I.L. Beales Leptin stimulates proliferation and inhibits apoptosis in Barrett's esophageal adenocarcinoma cells by cyclooxygenase-2-dependent, prostaglandin-E2-mediated transactivation of the epidermal growth factor receptor and c-Jun NH2-terminal kinase activation Endocrinology 147 2006 4505 4516
183. K. Ohinata, K. Suetsugu, Y. Fujiwara, and M. Yoshikawa Activation of prostaglandin E receptor EP4 subtype suppresses food intake in mice Prostaglandins Other Lipid Mediat 81 2006 31 36
184. T. Ohshiba, C. Miyaura, and A. Ito Role of prostaglandin E produced by osteoblasts in osteolysis due to bone metastasis Biochem Biophys Res Commun 300 2003 957 964
185. H. Oka, M. Miyauchi, H. Furusho, T. Nishihara, and T. Takata Oral administration of prostaglandin E(2)-specific receptor 4 antagonist inhibits lipopolysaccharide-induced osteoclastogenesis in rat periodontal tissue J Periodontol 83 2012 506 513
186. M. Okano, Y. Sugata, T. Fujiwara, R. Matsumoto, M. Nishibori, and K. Shimizu E prostanoid 2 (EP2)/EP4-mediated suppression of antigen-specific human T-cell responses by prostaglandin E2 Immunology 118 2006 343 352
187. T. Okumura, Y. Murata, K. Taniguchi, A. Murase, and A. Nii Effects of the selective EP4 antagonist, CJ-023,423 on chronic inflammation and bone destruction in rat adjuvant-induced arthritis J Pharm Pharmacol 60 2008 723 730
188. T. Okuyama, S. Ishihara, H. Sato, M.A. Rumi, K. Kawashima, and Y. Miyaoka Activation of prostaglandin E2-receptor EP2 and EP4 pathways induces growth inhibition in human gastric carcinoma cell lines J Lab Clin Med 140 2002 92 102
189. E.T. Olesen, M.R. Rutzler, H.B. Moeller, H.A. Praetorius, and R.A. Fenton Vasopressin-independent targeting of aquaporin-2 by selective E-prostanoid receptor agonists alleviates nephrogenic diabetes insipidus Proc Natl Acad Sci U S A 108 2011 12949 12954
190. K. Omote, T. Kawamata, Y. Nakayama, H. Yamamoto, M. Kawamata, and A. Namiki Effects of a novel selective agonist for prostaglandin receptor subtype EP4 on hyperalgesia and inflammation in monoarthritic model Anesthesiology 97 2002 170 176
191. H. Oshima, K. Hioki, B.K. Popivanova, K. Oguma, N. Van Rooijen, and T.O. Ishikawa Prostaglandin E(2) signaling and bacterial infection recruit tumor-promoting macrophages to mouse gastric tumors Gastroenterology 140 596-607 2011 e597
192. M.R. Pan, M.F. Hou, H.C. Chang, and W.C. Hung Cyclooxygenase-2 up-regulates CCR7 via EP2/EP4 receptor signaling pathways to enhance lymphatic invasion of breast cancer cells J Biol Chem 283 2008 11155 11163
193. T.Y. Park, E.J. Baik, and S.H. Lee Prostaglandin E(2) -induced intercellular adhesion molecule-1 expression is mediated by cAMP/Epac signaling modules in bEnd.3 brain endothelial cells Br J Pharmacol 2013 10.1111/bph.12103
194. G.Y. Park, and J.W. Christman Involvement of cyclooxygenase-2 and prostaglandins in the molecular pathogenesis of inflammatory lung diseases Am J Physiol Lung Cell Mol Physiol 290 2006 L797 L805
195. I.D. Pavord, C.S. Wong, J. Williams, and A.E. Tattersfield Effect of inhaled prostaglandin E2 on allergen-induced asthma Am Rev Respir Dis 148 1993 87 90
196. R.S. Peebles, K. Hashimoto, J.D. Morrow, R. Dworski, R.D. Collins, and Y. Hashimoto Selective cyclooxygenase-1 and -2 inhibitors each increase allergic inflammation and airway hyperresponsiveness in mice Am J Respir Crit Care Med 165 2002 1154 1160
197. S. Philipose, V. Konya, I. Sreckovic, G. Marsche, I.T. Lippe, and B.A. Peskar The prostaglandin E2 receptor EP4 is expressed by human platelets and potently inhibits platelet aggregation and thrombus formation Arterioscler Thromb Vasc Biol 30 2010 2416 2423
198. S. Philipose, M. Ofner, A. Heinemann, and R. Schuligoi Prostaglandin E2 acts via the EP4 receptor to inhibit platelet aggregation BMC Pharmacol 9 2009 (Abstract 8)
199. A. Poschke, N. Kern, T. Maruyama, H. Pavenstadt, S. Narumiya, and B.L. Jensen The PGE2-EP4 receptor is necessary for stimulation of the renin-angiotensin-aldosterone system in response to low dietary salt intake in vivo Am J Physiol Renal Fluid Electrolyte Physiol 303 2012 F1435 F1442
200. A. Pozzi, X. Yan, I. Macias-Perez, S. Wei, A.N. Hata, and R.M. Breyer Colon carcinoma cell growth is associated with prostaglandin E2/EP4 receptor-evoked ERK activation J Biol Chem 279 2004 29797 29804
201. G. Prasanna, J. Fortner, C. Xiang, E. Zhang, S. Carreiro, and S. Anderson Ocular pharmacokinetics and hypotensive activity of PF-04475270, an EP4 prostaglandin agonist in preclinical models Exp Eye Res 89 2009 608 617
202. M. Prijatelj, T. Celhar, M. Gobec, and I. Mlinaric-Rascan EP4 receptor signalling in immature B cells involves cAMP and NF-kappaB dependent pathways J Pharm Pharmacol 64 2012 1090 1098
203. M. Prijatelj, T. Celhar, and I. Mlinaric-Rascan Prostaglandin EP4 receptor enhances BCR-induced apoptosis of immature B cells Prostaglandins Other Lipid Mediat 95 2011 19 26
204. K.E. Purdy, and W.J. Arendshorst EP(1) and EP(4) receptors mediate prostaglandin E(2) actions in the microcirculation of rat kidney Am J Physiol Renal Fluid Electrolyte Physiol 279 2000 F755 F764
205. X. Qian, J. Zhang, and J. Liu Tumor-secreted PGE2 inhibits CCL5 production in activated macrophages through cAMP/PKA signaling pathway J Biol Chem 286 2011 2111 2120
206. R. Rao, R. Redha, I. Macias-Perez, Y. Su, C. Hao, and R. Zent Prostaglandin E2-EP4 receptor promotes endothelial cell migration via ERK activation and angiogenesis in vivo J Biol Chem 282 2007 16959 16968
207. A. Rasmuson, A. Kock, O.M. Fuskevag, B. Kruspig, J. Simon-Santamaria, and V. Gogvadze Autocrine prostaglandin E2 signaling promotes tumor cell survival and proliferation in childhood neuroblastoma PLoS One 7 2012 e29331
208. M.J. Ratcliffe, A. Walding, P.A. Shelton, A. Flaherty, and I.G. Dougall Activation of E-prostanoid4 and E-prostanoid2 receptors inhibits TNF-alpha release from human alveolar macrophages Eur Respir J 29 2007 986 994
209. J.W. Regan EP2 and EP4 prostanoid receptor signaling Life Sci 74 2003 143 153
210. J.W. Regan, T.J. Bailey, D.J. Pepperl, K.L. Pierce, A.M. Bogardus, J.E. Donello, C.E. Fairbairn, K.E. Kedzie, D.F. Woodward, and D.W. Gil Cloning of a novel human prostaglandin receptor with characteristics of the pharmacologically defined EP 2 subtype Mol. Pharmacol. 46 1994 213 220
211. J.B. Regard, I.T. Sato, and S.R. Coughlin Anatomical profiling of G protein-coupled receptor expression Cell 135 2008 561 571
212. J.B. Richards, L. Joseph, K. Schwartzman, N. Kreiger, A. Tenenhouse, and D. Goltzman The effect of cyclooxygenase-2 inhibitors on bone mineral density: results from the Canadian Multicentre Osteoporosis Study Osteoporos Int 17 2006 1410 1419
213. F. Rieder, M. Georgieva, A. Schirbel, M. Artinger, A. Zugner, and M. Blank Prostaglandin E2 inhibits migration of colonic lamina propria fibroblasts Inflamm Bowel Dis 16 2010 1505 1513
214. J.E. Rundhaug, M.S. Simper, I. Surh, and S.M. Fischer The role of the EP receptors for prostaglandin E2 in skin and skin cancer Cancer Metastasis Rev 30 2011 465 480
215. D. Sakata, C. Yao, and S. Narumiya Prostaglandin E2, an immunoactivator J Pharmacol Sci 112 2010 1 5
216. Y. Sakuma, K. Tanaka, M. Suda, A. Yasoda, K. Natsui, and I. Tanaka Crucial involvement of the EP4 subtype of prostaglandin E receptor in osteoclast formation by proinflammatory cytokines and lipopolysaccharide J Bone Miner Res 15 2000 218 227
217. R. Salcedo, X. Zhang, H.A. Young, N. Michael, K. Wasserman, and W.H. Ma Angiogenic effects of prostaglandin E2 are mediated by up-regulation of CXCR4 on human microvascular endothelial cells Blood 102 2003 1966 1977
218. K.J. Sales, A.A. Katz, M. Davis, S. Hinz, R.P. Soeters, and M.D. Hofmeyr Cyclooxygenase-2 expression and prostaglandin E(2) synthesis are up-regulated in carcinomas of the cervix: a possible autocrine/paracrine regulation of neoplastic cell function via EP2/EP4 receptors J Clin Endocrinol Metab 86 2001 2243 2249
219. E.W. Salzman, P.C. Kensler, and L. Levine Cyclic 3′,5′- adenosine monophosphate in human blood platelets. IV. Regulatory role of cyclic amp in platelet function Ann N Y Acad Sci 201 1972 61 71
220. B. Sastre, M. Fernandez-Nieto, E. Lopez, C. Gamez, E. Aguado, and S. Quirce PGE(2) decreases muscle cell proliferation in patients with non-asthmatic eosinophilic bronchitis Prostaglandins Other Lipid Mediat 95 2011 11 18
221. F. Schweda, J. Klar, S. Narumiya, R.M. Nusing, and A. Kurtz Stimulation of renin release by prostaglandin E2 is mediated by EP2 and EP4 receptors in mouse kidneys Am J Physiol Renal Fluid Electrolyte Physiol 287 2004 F427 F433
222. E. Segi, Y. Sugimoto, A. Yamasaki, Y. Aze, H. Oida, and T. Nishimura Patent ductus arteriosus and neonatal death in prostaglandin receptor EP4-deficient mice Biochem Biophys Res Commun 246 1998 7 12
223. + T regulatory cell activities in lung cancer Cancer Res 65 2005 5211 5220
224. A.F. Sheibanie, J.H. Yen, T. Khayrullina, F. Emig, M. Zhang, and R. Tuma The proinflammatory effect of prostaglandin E2 in experimental inflammatory bowel disease is mediated through the IL-23 → IL-17 axis J Immunol 178 2007 8138 8147
225. J. Shi, J. Johansson, N.S. Woodling, Q. Wang, T.J. Montine, and K. Andreasson The prostaglandin E2 E-prostanoid 4 receptor exerts anti-inflammatory effects in brain innate immunity J Immunol 184 2010 7207 7218
226. T. Shibata-Nozaki, H. Ito, H. Mitomi, J. Akaogi, T. Komagata, and T. Kanaji Endogenous prostaglandin E2 inhibits aberrant overgrowth of rheumatoid synovial tissue and the development of osteoclast activity through EP4 receptor Arthritis Rheum 63 2011 2595 2605
227. H. Shio, P.W. Ramwell, and S.J. Jessup Prostaglandin E2: effects on aggregation, shape change and cyclic AMP of rat platelets Prostaglandins 1 1972 29 36
228. T. Singh, M. Vaid, N. Katiyar, S. Sharma, and S.K. Katiyar Berberine, an isoquinoline alkaloid, inhibits melanoma cancer cell migration by reducing the expressions of cyclooxygenase-2, prostaglandin E(2) and prostaglandin E(2) receptors Carcinogenesis 32 2011 86 92
229. G.C.S. Smith The pharmacology of the ductus arteriosus Pharmacol Rev 50 1998 35 58
230. W.L. Smith, and D.L. Dewitt Prostaglandin endoperoxide H synthases-1 and -2 Adv Immunol 62 1996 167 215
231. J.P. Smith, E.V. Haddad, J.D. Downey, R.M. Breyer, and O. Boutaud PGE(2) decreases reactivity of human platelets by activating EP2 and EP4 Thromb Res 126 2010 E23 E29
232. K. Soontrapa, T. Honda, D. Sakata, C. Yao, T. Hirata, and S. Hori Prostaglandin E2-prostaglandin E receptor subtype 4 (EP4) signaling mediates UV irradiation-induced systemic immunosuppression Proc Natl Acad Sci U S A 108 2011 6668 6673
233. F. Spinella, L. Rosano, V. Di Castro, P.G. Natali, and A. Bagnato Endothelin-1-induced prostaglandin E2-EP2, EP4 signaling regulates vascular endothelial growth factor production and ovarian carcinoma cell invasion J Biol Chem 279 2004 46700 46705
234. J. Stachura, A. Tarnawski, K.J. Ivey, T. Mach, J. Bogdal, and J. Szczudrawa Prostaglandin protection of carbon tetrachloride-induced liver cell necrosis in the rat Gastroenterology 81 1981 211 217
235. B.A. Stillman, L. Audoly, and R.M. Breyer A conserved threonine in the second extracellular loop of the human EP2 and EP4 receptors is required for ligand binding Eur J Pharmacol 357 1998 73 82
236. E.M. Stitt-Cavanagh, W.H. Faour, K. Takami, A. Carter, B. Vanderhyden, and Y. Guan A maladaptive role for EP4 receptors in podocytes J Am Soc Nephrol 21 2010 1678 1690
237. A. Stock, S. Booth, and V. Cerundolo Prostaglandin E2 suppresses the differentiation of retinoic acid-producing dendritic cells in mice and humans J Exp Med 208 2011 761 773
238. M. Suda, K. Tanaka, K. Natsui, T. Usui, I. Tanaka, and M. Fukushima Prostaglandin E receptor subtypes in mouse osteoblastic cell line Endocrinology 137 1996 1698 1705
239. Y. Sugimoto, and S. Narumiya Prostaglandin E receptors J Biol Chem 282 2007 11613 11617
240. K. Suzuki, H. Araki, H. Mizoguchi, O. Furukawa, and K. Takeuchi Prostaglandin E inhibits indomethacin-induced gastric lesions through EP-1 receptors Digestion 63 2001 92 101
241. C. Suzuki, C. Miyamoto, T. Furuyashiki, S. Narumiya, and K. Ohinata Central PGE2 exhibits anxiolytic-like activity via EP1 and EP4 receptors in a manner dependent on serotonin 5-HT1A, dopamine D1 and GABAA receptors FEBS Lett 585 2011 2357 2362
242. J.-i Suzuki, M. Ogawa, R. Watanabe, K. Takayama, Y. Hirata, and R. Nagai Roles of prostaglandin E2 in cardiovascular diseases focus on the potential use of a novel selective EP4 receptor agonist Int Heart J 52 2011 266 269
243. T. Tada, and H. Kishimoto Ultrastructural and histological studies on closure of the mouse ductus arteriosus Acta Anatomica (Basel) 139 1990 326 334
244. T. Tajima, T. Murata, K. Aritake, Y. Urade, H. Hirai, and M. Nakamura Lipopolysaccharide induces macrophage migration via prostaglandin D(2) and prostaglandin E(2) J Pharmacol Exp Ther 326 2008 493 501
245. M. Takano, H. Nishimura, Y. Kimura, J. Washizu, Y. Mokuno, and Y. Nimura Prostaglandin E-2 protects against liver injury after Escherichia coli infection but hampers the resolution of the infection in mice J Immunol 161 1998 3019 3025
246. K. Takayama, G. Garcia-Cardena, G.K. Sukhova, J. Comander, M.A. Gimbrone, and P. Libby Prostaglandin E-2 suppresses chemokine production in human macrophages through the EP4 receptor J Biol Chem 277 2002 44147 44154
247. K. Takayama, G.K. Sukhova, M.T. Chin, and P. Libby A novel prostaglandin E receptor 4-associated protein participates in antiinflammatory signaling Circ Res 98 2006 499 504
248. I. Take, Y. Kobayashi, Y. Yamamoto, H. Tsuboi, T. Ochi, and S. Uematsu Prostaglandin E2 strongly inhibits human osteoclast formation Endocrinology 146 2005 5204 5214
249. K. Takeuchi, H. Araki, M. Umeda, Y. Komoike, and K. Suzuki Adaptive gastric cytoprotection is mediated by prostaglandin EP1 receptors: a study using rats and knockout mice J Pharmacol Exp Ther 297 2001 1160 1165
250. K. Takeuchi, K. Yagi, S. Kato, and H. Ukawa Roles of prostaglandin E-receptor subtypes in gastric and duodenal bicarbonate secretion in rats Gastroenterology 113 1997 1553 1559
251. M. Takita, M. Inada, T. Maruyama, and C. Miyaura Prostaglandin E receptor EP4 antagonist suppresses osteolysis due to bone metastasis of mouse malignant melanoma cells FEBS Lett 581 2007 565 571
252. G. Tamma, B. Wiesner, J. Furkert, D. Hahm, A. Oksche, and M. Schaefer The prostaglandin E2 analogue sulprostone antagonizes vasopressin-induced antidiuresis through activation of Rho J Cell Sci 116 2003 3285 3294
253. E.H.C. Tang, P. Libby, P.M. Vanhoutte, and A. Xu Anti-inflammation therapy by activation of prostaglandin EP4 receptor in cardiovascular and other inflammatory diseases J Cardiovasc Pharmacol 59 2012 116 123
254. L.L. Tang, K. Loutzenhiser, and R. Loutzenhiser Biphasic actions of prostaglandin E-2 on the renal afferent arteriole - role of EP3 and EP4 receptors Circ Res 86 2000 663 670
255. E.H.C. Tang, K. Shimizu, T. Christen, V.Z. Rocha, E. Shvartz, and Y. Tesmenitsky Lack of EP4 receptors on bone marrow-derived cells enhances inflammation in atherosclerotic lesions Cardiovasc Res 89 2011 234 243
256. E.H.C. Tang, E. Shvartz, K. Shimizu, V.Z. Rocha, C. Zheng, and D. Fukuda Deletion of EP4 on bone marrow-derived cells enhances inflammation and angiotensin II-induced abdominal aortic aneurysm formation Arterioscler Thromb Vasc Biol 31 2011 261 269
257. N. Terada, Y. Shimizu, T. Kamba, T. Inoue, A. Maeno, and T. Kobayashi Identification of EP4 as a potential target for the treatment of castration-resistant prostate cancer using a novel xenograft model Cancer Res 70 2010 1606 1615
258. K.H. Thierauch, and G. Prior Modulation of platelet activation by prostaglandin E2 mimics Adv Prostaglandin Thromboxane Leukot Res 21A 1991 383 386
259. A.V. Timoshenko, G. Xu, S. Chakrabarti, P.K. Lala, and C. Chakraborty Role of prostaglandin E2 receptors in migration of murine and human breast cancer cells Exp Cell Res 289 2003 265 274
260. C. Vancheri, C. Mastruzzo, M.A. Sortino, and N. Crimi The lung as a privileged site for the beneficial actions of PGE(2) Trends Immunol 25 2004 40 46
261. R. Vezza, R. Roberti, G.G. Nenci, and P. Gresele Prostaglandin E2 potentiates platelet aggregation by priming protein kinase C Blood 82 1993 2704 2713
262. S. Vukicevic, P. Simic, F. Borovecki, L. Grgurevic, D. Rogic, and I. Orlic Role of EP2 and EP4 receptor-selective agonists of prostaglandin E(2) in acute and chronic kidney failure Kidney Int 70 2006 1099 1106
263. K. Vuolteenaho, T. Moilanen, and E. Moilanen Non-steroidal anti-inflammatory drugs, cyclooxygenase-2 and the bone healing process Basic Clin Pharmacol Toxicol 102 2008 10 14
264. H.J. Weiss, A.L. Willis, D. Kuhn, and H. Brand Prostaglandin E2 potentiation of platelet aggregation induced by LASS endoperoxide: absent in storage pool disease, normal after aspirin ingestion Br J Haematol 32 1976 257 272
265. C.H. Wu, Y.W. Shih, C.H. Chang, T.T. Ou, C.C. Huang, and J.D. Hsu EP4 upregulation of Ras signaling and feedback regulation of Ras in human colon tissues and cancer cells Arch Toxicol 84 2010 731 740
266. J. Wu, Y. Zhang, N. Frilot, J.I. Kim, W.J. Kim, and Y. Daaka Prostaglandin E2 regulates renal cell carcinoma invasion through the EP4 receptor-Rap GTPase signal transduction pathway J Biol Chem 286 2011 33954 33962
267. Y.F. Xiao, G.L. Araldi, Z. Zhao, A. Reddy, S. Karra, and N. Brugger Synthesis and evaluation of a gamma-lactam as a highly selective EP2 and EP4 receptor agonist Bioorg Med Chem Lett 18 2008 821 824
268. C.Y. Xiao, K. Yuhki, A. Hara, T. Fujino, S. Kuriyama, and T. Yamada Prostaglandin E-2 protects the heart from ischemia-reperfusion injury via its receptor subtype EP4 Circulation 109 2004 2462 2468
269. -/- mice via activation of prostaglandin E2 receptor subtype 4 Am J Pathol 175 2009 772 785
270. X. Xin, M. Majumder, G.V. Girish, V. Mohindra, T. Maruyama, and P.K. Lala Targeting COX-2 and EP4 to control tumor growth, angiogenesis, lymphangiogenesis and metastasis to the lungs and lymph nodes in a breast cancer model Lab Invest 92 2012 1115 1128
271. E. Yamamoto, T. Izawa, V. Juniantito, M. Kuwamura, K. Sugiura, and T. Takeuchi Involvement of endogenous prostaglandin E2 in tubular epithelial regeneration through inhibition of apoptosis and epithelial-mesenchymal transition in cisplatin-induced rat renal lesions Histol Histopathol 25 2010 995 1007
272. L. Yang, Y. Huang, R. Porta, K. Yanagisawa, A. Gonzalez, and E. Segi Host and direct antitumor effects and profound reduction in tumor metastasis with selective EP4 receptor antagonism Cancer Res 66 2006 9665 9672
273. C. Yao, D. Sakata, Y. Esaki, Y. Li, T. Matsuoka, and K. Kuroiwa Prostaglandin E2-EP4 signaling promotes immune inflammation through Th1 cell differentiation and Th17 cell expansion Nat Med 15 2009 633 640
274. J.H. Yen, V.P. Kocieda, H.E. Jing, and D. Ganea Prostaglandin E2 induces matrix metalloproteinase 9 expression in dendritic cells through two independent signaling pathways leading to activator protein 1 (AP-1) activation J Biol Chem 286 2011 38913 38923
275. U. Yokoyama, R. Ishiwata, M.H. Jin, Y. Kato, O. Suzuki, and H. Jin Inhibition of EP4 signaling attenuates aortic aneurysm formation PLoS One 7 2012 e36724
276. U. Yokoyama, S. Minamisawa, H. Quan, T. Akaike, S. Suzuki, and M. Jin Prostaglandin E2-activated Epac promotes neointimal formation of the rat ductus arteriosus by a process distinct from that of cAMP-dependent protein kinase A J Biol Chem 283 2008 28702 28709
277. U. Yokoyama, S. Minamisawa, H. Quan, S. Ghatak, T. Akaike, and E. Segi-Nishida Chronic activation of the prostaglandin recepor EP4 promotes hyaluronan-mediated neointimal formation in the ductus arteriosus J Clin Invest 116 2006 3026 3034
278. K. Yoshida, H. Oida, T. Kobayashi, T. Maruyama, M. Tanaka, and T. Katayama Stimulation of bone formation and prevention of bone loss by prostaglandin E EP4 receptor activation Proc Natl Acad Sci U S A 99 2002 4580 4585
279. Y. Zhang, and Y. Daaka PGE2 promotes angiogenesis through EP4 and PKAC gamma pathway Blood 118 2011 5355 5364
280. N. Zidar, K. Odar, D. Glavac, M. Jerse, T. Zupanc, and D. Stajer Cyclooxygenase in normal human tissues - is COX-1 really a constitutive isoform, and COX-2 an inducible isoform? J Cell Mol Med 13 2009 3753 3763